PRIMATENE Drug Patent Profile
✉ Email this page to a colleague
When do Primatene patents expire, and what generic alternatives are available?
Primatene is a drug marketed by Armstrong Pharms and Wyeth Cons and is included in two NDAs. There is one patent protecting this drug.
The generic ingredient in PRIMATENE is epinephrine. There are twenty-one drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the epinephrine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Primatene
A generic version of PRIMATENE was approved as epinephrine by BPI LABS on July 29th, 2014.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for PRIMATENE?
- What are the global sales for PRIMATENE?
- What is Average Wholesale Price for PRIMATENE?
Summary for PRIMATENE
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| DailyMed Link: | PRIMATENE at DailyMed |
US Patents and Regulatory Information for PRIMATENE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Armstrong Pharms | PRIMATENE MIST | epinephrine | AEROSOL, METERED;INHALATION | 205920-001 | Nov 7, 2018 | OTC | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Wyeth Cons | PRIMATENE MIST | epinephrine | AEROSOL, METERED;INHALATION | 016126-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
